ASC Therapeutics is a clinical-stage biopharmaceutical company focused on developing, manufacturing, and commercializing potentially curative gene and cell therapies for individuals with debilitating diseases, primarily hematological disorders and other rare conditions. Leveraging its proprietary gene editing platforms and AAV-based gene replacement therapies, ASC Therapeutics aims to deliver transformative treatments to patients worldwide. The company has a state-of-the-art GMP manufacturing facility to support its clinical programs and future commercialization.
The headquarters serves as the central hub for research and development, clinical operations, GMP manufacturing, and corporate functions, driving the company's mission to advance gene and cell therapies.
Includes a state-of-the-art, in-house GMP (Good Manufacturing Practice) facility for viral vector production and cell processing, crucial for its gene and cell therapy programs.
ASC Therapeutics fosters a collaborative, innovative, and patient-focused work environment. Employees are driven by a shared mission to develop life-changing therapies, emphasizing scientific rigor, teamwork, and a commitment to quality.
The Alameda headquarters is strategically significant due to its co-location with advanced GMP manufacturing capabilities, enabling seamless integration from research to clinical production. Its presence in the San Francisco Bay Area provides access to a rich ecosystem of talent, research institutions, and investment.
While headquartered in the US, ASC Therapeutics conducts global clinical trials for its therapeutic candidates. Its focus is on developing therapies for patients worldwide, involving collaborations with international research institutions and healthcare providers. The company's manufacturing capabilities are designed to potentially support global commercialization in the future.
1900 Harbor Bay Parkway, Suite 115
Alameda
California
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ASCP' leadership includes:
ASCP has been backed by several prominent investors over the years, including:
Over the past year, ASC Therapeutics has seen a key leadership transition with Dr. Ruhong Jiang stepping down as CEO and Dr. Ronghao Li appointed as Interim CEO. The company also strengthened its executive team with the appointment of Gary D. Sclar as Chief Financial Officer.
Discover the tools ASCP uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
ASC Therapeutics likely utilizes a common professional email format for its employees. While specific internal email patterns are not publicly disclosed for security and privacy reasons, typical formats in the biopharmaceutical industry include variations of [first name], [last name], and initials. A common pattern is [first_initial][last]@[company_domain].com.
[first_initial][last]@asctherapeutics.com
Format
rli@asctherapeutics.com
Example
75%
Success rate
PR Newswire • November 21, 2023
ASC Therapeutics announced the appointment of Dr. Ronghao Li, current Chief Technology Officer, as Interim Chief Executive Officer, effective immediately. Dr. Ruhong Jiang has stepped down as CEO and will serve as a strategic advisor to the company....more
GlobeNewswire • May 23, 2023
ASC Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ASCTx-101 for the treatment of multiple myeloma. ASCTx-101 is an investigational autologous CAR-T cell therapy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ASCP, are just a search away.